The Pharmaceutical Continuous Manufacturing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pharmaceutical Continuous Manufacturing Market:
According to The Business Research Company’s Pharmaceutical Continuous Manufacturing Global Market Report 2024, The pharmaceutical continuous manufacturing market size has grown rapidly in recent years. It will grow from $2.26 billion in 2023 to $2.5 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to quality and efficiency improvements, reduced time-to-market, cost reduction and operational efficiency, regulatory support and guidelines, flexibility and scalability.
The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $3.71 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing generic drug production, biopharmaceutical manufacturing, personalized medicine manufacturing, focus on patient-centric approaches. Major trends in the forecast period include adoption of continuous manufacturing, integration of process analytical technology, use of advanced automation and robotics, strategic collaborations and partnerships, digitalization and connectivity.
The growing prevalence of several chronic ailments is expected to propel the growth of the pharmaceutical continuous manufacturing market going forward. Chronic ailments are described generically as problems that persist for a year or longer, need continuing medical treatment, and interfere with everyday activities. Continuous manufacturing processes enable pharmaceutical companies to streamline medication production, resulting in increased efficiency and lower costs. It also enables broader access to essential drugs, which is especially important for managing chronic conditions that require long-term medication use. For instance, in April 2022, according to a report published by the National Association of Chronic Disease Directors (NACDD), a US-based non-profit Public Health organization dedicated to chronic disease programs, almost 60 % of adult Americans have at least one chronic disease, and approximately 40% of American adults have multiple chronic conditions (MCC), and this is expected to cost the US economy $2 trillion dollars annually, or $8,600 per person by 2030. Therefore, the growing prevalence of several chronic ailments will drive the pharmaceutical continuous manufacturing market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12123&type=smp
The pharmaceutical continuous manufacturing market covered in this report is segmented –
1) By Product: Integrated Continuous System, Control And Software, Semi-Continuous System
2) By Therapeutics Type: Large Molecule, Small Molecule
3) By Formulation: Solid Formation, Liquid And Semi-Solid Formation
4) By Application: Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing
5) By End-Users: Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users
Technological innovations are a key trend gaining popularity in the pharmaceutical continuous manufacturing market. Major companies operating in the pharmaceutical continuous manufacturing market are developing new products to sustain their position in the market. For instance, in December 2022, The United States Pharmacopeia (USP), a US-based nonprofit organization that holds the trademark as well as the copyright on the Pharmacopeia National Formulary (USP-NF), introduced the USP Advanced Manufacturing Technology Lab with the launch of R&D analytical solutions. These analytical lab services would aid drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM), to increase geographic diversity in pharmaceutical manufacturing and support medicine supply chain resilience. This would describe materials and create and qualify ways to assist and assure the quality of PCM-based medications.
The pharmaceutical continuous manufacturing market report table of contents includes:
1. Executive Summary
2. Pharmaceutical Continuous Manufacturing Market Characteristics
3. Pharmaceutical Continuous Manufacturing Market Trends And Strategies
4. Pharmaceutical Continuous Manufacturing Market – Macro Economic Scenario
5. Global Pharmaceutical Continuous Manufacturing Market Size and Growth
.
.
.
26. South America Pharmaceutical Continuous Manufacturing Market
27. Brazil Pharmaceutical Continuous Manufacturing Market
28. Middle East Pharmaceutical Continuous Manufacturing Market
29. Africa Pharmaceutical Continuous Manufacturing Market
30. Pharmaceutical Continuous Manufacturing Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc.
- Robert Bosch GmbH
- Siemens AG
- Novartis AG
- Thermo Fisher Scientific Inc
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 029
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
